Lumboaortic and iliac lymphadenectomy for lymph node recurrence of colorectal cancer: prognostic value of the MSI phenotype.
BACKGROUND
Some patients have isolated lumboaortic and/or iliac lymph node recurrences (ILNR) of colorectal cancer. Current guidelines recommend the use of chemotherapy. The aim of our study was to assess the carcinological results of lymphadenectomy for ILNR and to identify prognostic factors that may be used to select patients for this aggressive surgical approach.


METHODS
Medical notes, pathological findings, and surgical procedure of patients who underwent lymphadenectomy for ILNR of colorectal cancer between 1998 and 2005 were reviewed.


RESULTS
Ten patients (four women) underwent lymphadenectomy for ILNR. Lymphadenectomy was performed after a mean of 37 +/- 16.6 months after colon or rectal resection. Two patients developed a postoperative complication. Mean number of lymph nodes removed was 5.7 +/- 3.3. After a median follow-up of 30.7 months, four patients were alive, including two patients without recurrence at 95 and 96 months after colectomy and two with local and distant recurrences at 114 and 70 months. Among the three patients with microsatellite-unstable (MSI) tumors, two were free of disease at 61 and 81 months, respectively, and one died of recurrent disease 20 months after lymphadenectomy.


CONCLUSIONS
Lymphadenectomy for ILNR of colorectal cancer is a feasible therapeutic option for selected patients. These preliminary results suggest that resection should be proposed for MSI patients because cure is possible, but to be confirmed, the findings require larger studies.
Lefevre
Jeremie H
JH
Department of Digestive Surgery, Hospital Saint-Antoine AP-HP, University Paris VI (Pierre and Marie Curie), 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. jeremie.lefevre@sat.aphp.fr
Rondelli
Fabio
F
Mourra
Najat
N
Bennis
Malika
M
Tiret
Emmanuel
E
Parc
Rolland
R
Parc
Yann
Y
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics; D000328:Adult; D015179:Colorectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000601:surgery*; D019175:DNA Methylation; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000378:metabolism / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000235:genetics / Q000601:surgery*; D009367:Neoplasm Staging; D009687:Nuclear Proteins / Q000235:genetics; D011183:Postoperative Complications; D011379:Prognosis; D015996:Survival Rate
D048868:Adaptor Proteins, Signal Transducing; C501486:MLH1 protein, human; D009687:Nuclear Proteins; C497172:MSH2 protein, human; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein